Chemical Property of CID 9873190
Chemical Property:
- Appearance/Colour:white to off-white crystalline solid
- Vapor Pressure:6.67E-21mmHg at 25°C
- Melting Point:196-198 °C
- Boiling Point:705.7 °C at 760 mmHg
- Flash Point:380.6 °C
- PSA：122.85000
- Density:1.173
- LogP:4.72450
- Storage Temp.:-20°C Freezer
- Solubility.:H2O: >20mg/mL
- Hydrogen Bond Donor Count:1
- Hydrogen Bond Acceptor Count:7
- Rotatable Bond Count:15
- Exact Mass:586.29095909
- Heavy Atom Count:40
- Complexity:850
- Purity/Quality:
-
99% *data from raw suppliers
Fosinopril-d5 Sodium Salt *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2CC(CC2C(=O)O)C3CCCCC3.[Na]
- Isomeric SMILES:CCC(=O)O[C@H](C(C)C)O[P@](=O)(CCCCC1=CC=CC=C1)CC(=O)N2C[C@@H](C[C@H]2C(=O)O)C3CCCCC3.[Na]
-
Description
Fosinopril sodium, an ester prodrug of fosinoprilat, is the first of a new generation of
phosphinic acid ACE inhibitors indicated for the once-daily treatment of hypertension.
Unlike captopril and lisinopril, it is reportedly effective in increasing the left
ventricular peak filling rates and peak ejection rates in hypertensive patients at rest.
Another advantage is that fosinopril sodium is metabolized equally by renal and hepatic
routes, thereby avoiding the requirement to modify dosage in patients with renal
insufficiency.
-
Uses
A phosphinic acid containing angiotensin converting enzyme (ACE) inhibitor. Antihypertensive. A labelled phosphinic acid containing angiotensin converting enzyme (ACE) inhibitor. Fosinopril sodium is the ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor, used for the treatment of hypertension and some types of chronic heart failure.
-
Therapeutic Function
Antihypertensive
-
Clinical Use
Angiotensin-converting enzyme inhibitor:
Hypertension
Heart failure
-
Drug interactions
Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect. Analgesics: antagonism of hypotensive effect and
increased risk of renal impairment with NSAIDs;
hyperkalaemia with ketorolac and other NSAIDs.
Antihypertensives: increased risk of hyperkalaemia,
hypotension and renal failure with ARBs and
aliskiren.
Bee venom extract: possible severe anaphylactoid
reactions when used together.
Ciclosporin: increased risk of hyperkalaemia and
nephrotoxicity.
Cytotoxics: increased risk of angioedema with
everolimus.
Diuretics: enhanced hypotensive effect;
hyperkalaemia with potassium-sparing diuretics.
ESAs: increased risk of hyperkalaemia; antagonism
of hypotensive effect.
Gold: flushing and hypotension with sodium
aurothiomalate.
Lithium: reduced excretion, possibility of enhanced
lithium toxicity.
Potassium salts: increased risk of hyperkalaemia.
Tacrolimus: increased risk of hyperkalaemia and
nephrotoxicity.
